20 / 31
Volume 3, Issue 4 (Suppl)
Polym Sci
ISSN: 2471-9935 Polym Sci, an open access journal
October 12-13, 2017 Osaka, Japan
Annual Meeting on
Biopolymers and Drug Delivery Systems
Biopolymers Meeting 2017
October 12-13 2017
Page 61
Polym Sci 2017, 3:4
DOI: 10.4172/2471-9935-C1-006
Drug delivery across the brain protective barriers
Alain L Fymat
International Institute of Medicine and Science, USA
T
here are approximately 400 known neural disorders some of which being due to a disruption or failure of the blood brain barrier
(BBB) such as, for example: meningitis (an inflammation of the meninges or membranes surrounding the brain and spinal cord),
epilepsy (chronic or acute seizures caused by inflammation), multiple sclerosis (MS-a disease of the immune system or/and the
breaking down of the BBB in a section of the brain or spinal cord), Alzheimer disease (AD-a disease in which amyloid beta contained
in blood plasma enter the brain and adhere to the surface of astrocytes), possibly prion and prion-like diseases such as Parkinson
disease (PD) and AD, HIV encephalitis (a precursor of HIV-associated dementia in which latent HIV can cross the BBB inside
circulating monocytes in the blood stream) and systemic inflammation (sterile or infectious) that may lead to effects on the brain,
cause sickness behavior and induce or/and accelerate brain diseases such as MS and PD. There are currently active investigations into
treatments for a compromised BBB. As a consequence of the growing aging population, many such neurodegenerative diseases, cancer
and infections of the brain will become more prevalent. Of interest here are those disorders requiring treatment by delivery of drugs
across the brain protective barriers. I will review the difficulties inherent in the delivery of drugs across the BBB in the treatment if the
above neurological disorders and discuss the mechanisms for drug targeting both “through” and “behind” the BBB. I will also suggest
approaches for the enhancement of drug delivery including physiological approaches, chemical and biological delivery and disruption
of the BBB system, the use of molecular Trojan horse systems and the various nanoparticle and nano delivering devices.
alain.fymat@fiimas.org